Lenire Sponsors Military Veterans Hearoes Tour
Lenire is sponsoring the 10th Annual Hearoes Tour to expand access to hearing and tinnitus care for U.S. veterans through free nationwide screenings and support.
Lenire is sponsoring the 10th Annual Hearoes Tour to expand access to hearing and tinnitus care for U.S. veterans through free nationwide screenings and support.
Neuromod's Lenire tinnitus device is available as a treatment option for U.S. veterans and other federal health services patients.
Neuromod Devices Ltd has announced the formation of a global commercial leadership team to direct the commercialization of its Lenire tinnitus treatment device through key partnerships.
The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.
Read MoreThe clinical trial was conducted between 2016 and 2019 and was designed to track changes in tinnitus symptom severity. The trial investigated the bimodal neuromodulation approach, using Neuromod’s non-invasive stimulation device that delivers sound to the ears and electrical stimulation to the tongue.
Read MoreIn addition to her current responsibilities for corporate development and strategy, Ms Tully will now assume responsibility for all of Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality, and compliance functions. Ms Tully will continue to report to Dr Ross O’Neill, Chief Executive Officer of Neuromod.
Read MoreElsaesser, a hearing aid industry expert, has worked in the sector for over 12 years in various executive positions for Sivantos and Siemens Audiology.
Read MoreThe American Tinnitus Association (ATA) and British Tinnitus Association (BTA) have announced...
Read MoreProceeds from the financing will be used to accelerate ongoing European commercialization of the Company’s Lenire tinnitus treatment device; to scale-up manufacturing capacity to meet anticipated European demand, and to progress the Company’s US regulatory strategy to secure market entry into the United States, according to Neuromod’s announcement.
Read MoreNeuromod announces the appointment of Deborah Arthur as Head of Quality and Regulatory Affairs, Suzanne O’Rourke as Director of Quality and Regulatory Affairs, and Cathal Mc Fadden as Director of Operations.
Read MoreA clinical expert in tinnitus and audiology, Tyler is a pioneer in the advancement of tinnitus research and treatment, founding the annual International Conference on Management of Tinnitus and Hyperacusis more than 26 years ago.
Read MoreNeuromod Devices Limited (“Neuromod”), an Irish medical technology company specializing in non-invasive neuromodulation technologies, is pleased to announce that Christopher M. Smith is a Strategic Advisor to the Board as of June 1, 2018 and will join the company’s Board of Directors from January 3, 2019.
Read MoreThis conference is intended for otologists, audiologists, psychologists, hearing aid specialists, and nurses who provide clinical management services for patients with tinnitus.
Read MoreLim’s work has a strong focus on the improvement of invasive and non-invasive neurostimulation approaches for treating unmet medical needs in hearing and other therapeutic areas.
Read MoreNeuromod Devices announced that it has secured the CE Mark—certified regulatory approval in Europe—for its mutebutton multisensory tinnitus treatment device.
Read More